| Gene symbol | CD5 | Synonyms | LEU1, T1 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD5 molecule | ||||
| GTO ID | GTC2854 |
| Trial ID | NCT05138458 |
| Disease | T-Cell Lymphoma | Mycosis Fungoides | Peripheral T-Cell Lymphoma |
| Altered gene | CD5 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD5 ATAK |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL |
| Year | 2021 |
| Country | United States |
| Company sponsor | Myeloid Therapeutics |
| Other ID(s) | MTX-TCL-101 |
| Cohort 1 | |||||||||
|
|||||||||